A research study looking into blood levels of the medicine NNC0487 0111 in the body and how well it is tolerated in people with reduced liver function and normal liver function

Start 12 May 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 2 sites · Protocol NN9490-8156

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other

Status Ongoing, recruiting

Participants planned 35

Countries 1

Sites 2

hepatic impairment

Key facts

Sponsor: Novo Nordisk A/S
Participant type: Patients, Healthy volunteers
Age range: 18-64 years
Gender: Male and Female
Therapeutic area: Not possible to specify
Trial duration: 12 May 2026 → ongoing
Decision date (initial): 2026-04-27
Transition trial: No
Low-intervention: No
Rare-disease indication: No
Vulnerable population: No

External identifiers

EU CT number: 2025-521647-20-00
WHO UTN: U1111-1320-4875

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

hepatic impairment

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Novo Nordisk A/S

Sponsor organisation: Novo Nordisk A/S
Address: Novo Alle 1
City: Bagsvaerd
Postcode: 2880
Country: Denmark

Scientific contact point

Organisation: Novo Nordisk A/S
Contact name: EU Submission Hub

Public contact point

Organisation: Novo Nordisk A/S
Contact name: EU Submission Hub

Locations

1 EU/EEA country · 2 investigational sites

By country

Country	MS status	Planned subjects	Sites
Slovakia	Ongoing, recruiting	35	2
Rest of world	—	0	—

Investigational sites

Slovakia

2 sites · Ongoing, recruiting

Summit Clinical Research s.r.o.

Zariadenie biomedicinskeho vyskumu, Duklianskych Hrdinov 34, 901 01, Malacky